Blood-based biomarkers for early diagnosis of lung cancer: A review article

16Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Lung cancer is the severe leading cause of cancer-related mortality worldwide. Early detection of lung cancer can significantly increase their survival rate. However, conventional lung cancer screening methods such as sputum cytology, chest X-rays, low-dose computed tomography, positron emission tomography, and magnetic resonance imaging, are radiational, and also expensive methods. Similarly, lung tumor tissue as invasive and difficult to obtain and potentially risky procedures, there is the immediate need of non-invasive, novel sensitive and reliable blood-based tumor markers which now has become an important area on research. This review will mainly focus on recently identified circulating biomarkers: circulating tumor cells, circulating tumor deoxyribonucleic acid, tumor-derived exosomes, circulating ribonucleic acid and micro ribonucleic acid, and tumor-educated platelets which may enable earlier diagnosis of lung cancer and their application in clinical practices.

Cite

CITATION STYLE

APA

Maharjan, N., Thapa, N., & Tu, J. (2020). Blood-based biomarkers for early diagnosis of lung cancer: A review article. Journal of the Nepal Medical Association. Nepal Medical Association. https://doi.org/10.31729/jnma.5023

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free